# Enoxaparin for Primary Thromboprophylaxis in Ambulatory Patients With COVID-19

Study · id `cardio:ct-nct04400799` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT04400799](<https://clinicaltrials.gov/study/NCT04400799>), retrieved 31 October 2026. No person wrote or checked this page.

Also called: NCT04400799

Browse, organ or system: Heart; Blood vessels  
Browse, condition area: Coronary and vascular disease  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is terminated. It enrolled 475 participants.

## Technical summary

Registry record NCT04400799. Randomized; no masking; primary purpose treatment. Start 2020-06-15 (actual); primary completion 2022-02-07 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 475 participants (enrolled count; ClinicalTrials.gov record NCT04400799, source copy `cardio:ctgov-nct04400799-2022-05-25`, retrieved 2026-10-31)
- Started: 2020-06-15 (actual) (ClinicalTrials.gov record NCT04400799, source copy `cardio:ctgov-nct04400799-2022-05-25`, retrieved 2026-10-31)
- Primary completion: 2022-02-07 (actual) (ClinicalTrials.gov record NCT04400799, source copy `cardio:ctgov-nct04400799-2022-05-25`, retrieved 2026-10-31)
- Completion: 2022-04-12 (actual) (ClinicalTrials.gov record NCT04400799, source copy `cardio:ctgov-nct04400799-2022-05-25`, retrieved 2026-10-31)
- Countries: Germany; Switzerland (ClinicalTrials.gov record NCT04400799, source copy `cardio:ctgov-nct04400799-2022-05-25`, retrieved 2026-10-31)
- Care setting: Not reported
- Registry status: "TERMINATED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct04400799-2022-05-25`, retrieved 2026-10-31)

## The registry's words

- Brief title: Enoxaparin for Primary Thromboprophylaxis in Ambulatory Patients With COVID-19
- Condition: COVID-19
- Condition: Pulmonary Embolism, Deep Vein Thrombosis
- Intervention (Drug): Enoxaparin 40Mg/0.4Ml Inj Syringe 0.4Ml
- Lead sponsor: University of Zurich
- Lead sponsor class: OTHER
- Collaborator: Insel Gruppe AG, University Hospital Bern
- Collaborator class: OTHER
- Collaborator: University Hospital, Geneva
- Collaborator class: OTHER
- Collaborator: Centre Hospitalier Universitaire Vaudois
- Collaborator class: OTHER
- Collaborator: University Hospital, Basel, Switzerland
- Collaborator class: OTHER
- Collaborator: Oncology Institute of Southern Switzerland
- Collaborator class: OTHER
- Collaborator: Clinica Luganese Moncucco
- Collaborator class: OTHER
- Collaborator: University Hospital Freiburg
- Collaborator class: OTHER
- Collaborator: Mainz University
- Collaborator class: OTHER

## Connected pages

- Registry condition terms include this condition: Deep vein thrombosis (`cardio:deep-vein-thrombosis`)
- Registry condition terms include this condition: Pulmonary embolism (`cardio:pulmonary-embolism`)
- Registry lists this organization as the lead sponsor: University of Zurich (`cardio:org-university-of-zurich`)
- Registry lists this organization as a collaborator: Insel Gruppe AG, University Hospital Bern (`cardio:org-insel-gruppe-ag-university-hospital-bern`)
- Registry lists this organization as a collaborator: University Hospital, Geneva (`cardio:org-university-hospital-geneva`)
- Registry lists this organization as a collaborator: University Hospital, Basel, Switzerland (`cardio:org-university-hospital-basel-switzerland`)

### Other papers using this trial's data

- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Enoxaparin for primary thromboprophylaxis in symptomatic outpatients with COVID-19 (OVID): a randomised, open-label, parallel-group, multicentre, phase 3 trial (`cardio:pubmed-35779558`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: 5417755244b3126bf906d97abc439c878b4ac510077ad6df4702a1095c7e75f6
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
